ODTX Stock — Odyssey Therapeutics Inc.: Cash, EV, Pipeline

Share price

$24.38

Market cap

$1,171.7M

Cash

$310.6M

Enterprise value

$861.1M

Balance sheet

Cash	$310.6M
Debt	$0.0M
Net cash	$310.6M
Enterprise value	$861.1M
Basic shares	47.9M shares
Fully diluted shares	62.3M shares
Fully diluted market cap	$1,518.6M
Cash per share	$6.48

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ODTX daily closes…

Loading price history…

Pipeline assets

OD-001

Phase 2 · Active

Target RIPK2

Indications

not disclosed (Phase 2)

Status note Most advanced product candidate, in a Phase 2a monotherapy trial. No indication, target or modality stated in the 10-Q excerpts.

OD-002

Preclinical · Active

Target SLC15A4

Indications

not disclosed (Preclinical)

Status note In IND-enabling studies. No indication, target or modality stated in the 10-Q excerpts.

NLRP1 program

Discovery · Active

Target NLRP1

Indications

not disclosed (Discovery)

Status note Drug discovery program (IFM acquisition). No indication, phase or modality stated in the 10-Q excerpts.

MDA5 program

Discovery · Active

Target MDA5

Indications

not disclosed (Discovery)

Status note Drug discovery program (IFM acquisition). No indication, phase or modality stated in the 10-Q excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	OD-07656
Lead indication	Ulcerative Colitis (UC)
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06850727	Phase 2	Recruiting	Sponsor	Odyssey Therapeutics	—	Ulcerative Colitis (UC); UC - Ulcerative Colitis	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Odyssey Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	3,001,198	+3,001,198	1.06%	2026-08-14
Logos Global Management	521,736	+521,736	0.42%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ODTX — Odyssey Therapeutics Inc.

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials

Institutional holders